Imunon Registers 20M Shares Plus 70M Warrants in Best-Efforts Follow-On

summarizeSummary

Imunon filed the S-1 for its previously announced best-efforts offering: 20 million shares at an assumed $1.25 plus 70 million warrants across four tranches, for roughly $23 million net if fully sold. The raise funds a going-concern-stage biotech at the cost of heavy dilution and a large warrant overhang.

check_boxKey Events · Financing and Capital Events · IMNN

• Best-Efforts Offering Registered

  Up to 20,000,000 shares at an assumed combined price of $1.25 per share and accompanying warrants, sold through Maxim Group as placement agent with no minimum offering amount.

• 350% Warrant Coverage in Four Tranches

  Buyers receive 70,000,000 common warrants: Tranche A at $1.25 (50% coverage), Tranche B at $1.38, Tranche C at $1.56 and Tranche D at $2.50 (100% each), with early expiry tied to OVATION 3 milestones if the stock trades at 300% of strike for 30 days.

• Roughly $23 Million Net If Fully Sold

  Estimated net proceeds of approximately $23 million after a 7.0% placement fee, 5.0% placement agent warrants and up to $125,000 of expense reimbursement; $17.2M, $11.4M and $5.6M if only 75%, 50% or 25% is sold.

• Share Count Would Rise to 24.67 Million

  From 4,665,660 shares outstanding as of June 30, 2026, the full share sale takes the count to 24,665,600, with immediate dilution of $0.22 per share to new investors against as-adjusted net tangible book value of $1.03.

auto_awesomeAnalysis · IMNN · Life Sciences

The registration statement behind the $25 million best-efforts raise Imunon announced in its 8-K is now on file, and it puts hard numbers on the terms for the first time. Imunon would sell 20 million shares at an assumed $1.25 combined price — roughly $25 million gross, about $23 million net — and hand buyers 70 million warrants across four tranches struck at $1.25 to $2.50, with each tranche expiring early if OVATION 3 hits specified clinical milestones while the stock trades at 300% of the strike. Against 4.67 million shares outstanding as of June 30, 2026, the share sale alone would take the count to 24.67 million, and the warrant overhang is more than four times that. For a company that entered the year with a going-concern warning and $6.9 million of cash, the capital is survival money; the cost is that existing holders absorb immediate dilution of $0.22 per share and a very large potential future share supply. Pricing is not yet set — the $1.25 is the October 23, 2026 closing price used for illustration, and the actual price will be negotiated at launch and may be at a discount.